Showing 3851-3860 of 8196 results for "".
- Remibrutinib Shows Positive Effects on Sleep, Daily Activities for CSU Patientshttps://practicaldermatology.com/news/Remibrutinib-Shows-Positive-Effects-Sleep-Daily-Activities-CSU-Patients/2471637/Remibrutinib’s impact on sleep deprivation and daily activities for patients with chronic spontaneous urticaria (CSU) were highlighted in a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Robert Snyder, MD, FAAD, presented “Effect of Remib
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- New Tapinarof Data Promising for Children and Perhaps Morehttps://practicaldermatology.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure
- Benzene Update at AAD Discusses Both Regulations and Health Riskshttps://practicaldermatology.com/news/Benzene-Update-AAD-Discusses-Both-Regulations-Health-Risks/2471605/Christopher Bunick, MD, PhD, FAAD, made waves at the 2024 American Academy of Dermatology (AAD) Annual Meeting with his presentation about benzene in benzoyl peroxide (BPO) products for acne treatments. At the 2025 AAD Annual Meeting in Orlando, Florida, Dr. Bunick provided an update on the resea
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202
- Report: L'Oreal Recalling BPO Product Due to Benzenehttps://practicaldermatology.com/news/Report-LOreal-Recalling-BPO-Product-Due-Benzene/2471598/L’Oreal SA is recalling La Roche-Posay’s benzoyl peroxide acne treatment, Effaclar Duo, in the US because of “concern that the creams are contaminated with benzene,” Bloomberg News reported. L’Oreal said testing found trace levels of benzene in one lot product, according to Bloomberg.
- New Spesolimab Data Indicate Impact on Both Physical, Mental Healthhttps://practicaldermatology.com/news/New-Spesolimab-Data-Indicate-Impact-Both-Physical-Mental-Health/2471581/New analyses of the effects of spesolimab on the physical symptoms and mental health burden associated with generalized pustular psoriasis (GPP) were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. These post-hoc exploratory analyses from the
- Incoming AAD President Dr. Taylor Pledges to 'Take Care of Dermatologists'https://practicaldermatology.com/news/Incoming-AAD-President-Dr-Taylor-Pledges-Take-Care-Dermatologists/2471549/The theme of the next American Academy of Dermatology (AAD) presidency will be taking care of dermatologists so that they can take care of their patients, incoming president Susan C. Taylor, MD, FAAD, said in an address at the 2025 AAD Annual Meeting in Orlando, Florida. “Just as we treat
- Dr. Desai Reflects on AAD's Progress Over Past Yearhttps://practicaldermatology.com/news/Dr-Desai-Reflects-AAD-Progress-Over-Past-Year/2471547/Seemal Desai, MD, FAAD, achieved his dream and propelled the profession forward during his year as American Academy of Dermatology (AAD) president, but work remains to be done, he said in his farewell address at the 2025 AAD Annual Meeting in Orlando, Florida. “This year as your president